文献速递MDS 与骨髓增殖性肿瘤

帕克替尼对比最佳可用疗法治疗骨髓纤维化(不论基线血细胞减少):国际随机3期PERSIST-1试验

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
PubMed 文献 · Lancet Haematol · 2017-03-20

这项国际多中心随机3期试验在12个国家67个中心纳入327例高危骨髓纤维化患者,按2:1随机接受口服帕克替尼400 mg每日一次或排除JAK2抑制剂的最佳可用疗法。第24周脾体积缩小≥35%的患者比例帕克替尼组为19%(42例),最佳可用疗法组为5%(5例),p=0.0003。帕克替尼耐受性良好,可成为骨髓纤维化尤其基线血细胞减少患者的治疗选择。

要点

  • 第24周脾体积缩小≥35%:帕克替尼组19%(42/220)vs 最佳可用疗法组5%(5/107),p=0.0003。
  • 帕克替尼组最常见3-4级不良事件为贫血17%、血小板减少12%、腹泻5%。
  • 帕克替尼组因不良事件死亡27例(12%),最佳可用疗法组14例(13%)。

核心结论

  • 帕克替尼治疗耐受性良好,即使在基线严重血细胞减少的患者中也能诱导显著且持续的脾体积缩小和症状减轻。
  • 帕克替尼可作为骨髓纤维化患者的治疗选择,包括治疗选择尤其有限的基线血细胞减少患者。

研究设计与样本

  • 国际、多中心、随机、3期试验(PERSIST-1),在12个国家67个中心进行。
  • 纳入高危骨髓纤维化患者,不排除基线贫血或血小板减少。
  • 按2:1随机分配接受口服帕克替尼400 mg每日一次或排除JAK2抑制剂的最佳可用疗法,直至疾病进展或不可耐受毒性。
  • 随机分层因素为风险类别、血小板计数和地区。
  • 主要终点为意向治疗人群中第24周经盲法中心审阅MRI或CT评估的脾体积较基线缩小≥35%。

主要发现

  • 2013年1月8日至2014年8月1日共随机分配327例患者至帕克替尼组(n=220)或最佳可用疗法组(n=107)。
  • 中位随访23.2个月(IQR 14.8-28.7)。
  • 第24周主要终点脾体积缩小≥35%:帕克替尼组42例(19%)vs 最佳可用疗法组5例(5%),p=0.0003。
  • 最佳可用疗法组90例患者在中位6.3个月(IQR 5.8-6.7)时交叉接受帕克替尼治疗。
  • 截至第24周,帕克替尼组最常见3-4级不良事件为贫血37例(17%)、血小板减少26例(12%)、腹泻11例(5%);最佳可用疗法组为贫血16例(15%)、血小板减少12例(11%)、呼吸困难3例(3%)、低血压3例(3%)。

关键数值与推荐

  • 主要终点脾体积缩小≥35%:帕克替尼组19%(42/220)vs 最佳可用疗法组5%(5/107),p=0.0003。
  • 帕克替尼组3-4级贫血17%(37例),3-4级血小板减少12%(26例),3-4级腹泻5%(11例)。
  • 最佳可用疗法组3-4级贫血15%(16例),3-4级血小板减少11%(12例),3-4级呼吸困难3%(3例),3-4级低血压3%(3例)。

临床怎么用

  • 帕克替尼可作为骨髓纤维化患者的治疗选择,包括基线血细胞减少、治疗选择尤其有限的患者(作者认为)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Available therapies for myelofibrosis can exacerbate cytopenias and are not indicated for patients with severe thrombocytopenia. Pacritinib, which inhibits both JAK2 and FLT3, induced spleen responses with limited myelosuppression in phase 1/2 trials. We aimed to assess the efficacy and safety of pacritinib versus best available therapy in patients with myelofibrosis irrespective of baseline cytopenias. METHODS: This international, multicentre, randomised, phase 3 trial (PERSIST-1) was done at 67 sites in 12 countries. Patients with higher-risk myelofibrosis (with no exclusions for baseline anaemia or thrombocytopenia) were randomly assigned (2:1) to receive oral pacritinib 400 mg once daily or best available therapy (BAT) excluding JAK2 inhibitors until disease progression or unacceptable toxicity. Randomisation was stratified by risk category, platelet count, and region. Treatment assignments were known to investigators, site personnel, patients, clinical monitors, and pharmacovigilance personnel. The primary endpoint was spleen volume reduction (SVR) of 35% or more from baseline to week 24 in the intention-to-treat population as assessed by blinded, centrally reviewed MRI or CT. We did safety analyses in all randomised patients who received either treatment. Here we present the final data. This trial is registered with ClinicalTrials.gov, number NCT01773187. FINDINGS: Between Jan 8, 2013, and Aug 1, 2014, 327 patients were randomly assigned to pacritinib (n=220) or BAT (n=107). Median follow-up was 23·2 months (IQR 14·8-28·7). At week 24, the primary endpoint of SVR of 35% or more was achieved by 42 (19%) patients in the pacritinib group versus five (5%) patients in the BAT group (p=0·0003). 90 patients in the BAT group crossed over to receive pacritinib at a median of 6·3 months (IQR 5·8-6·7). The most common grade 3-4 adverse events through week 24 were anaemia (n=37 [17%]), thrombocytopenia (n=26 [12%]), and diarrhoea (n=11 [5%]) in the pacritinib group, and anaemia (n=16 [15%]), thrombocytopenia (n=12 [11%]), dyspnoea (n=3 [3%]), and hypotension (n=3 [3%]) in the BAT group. The most common serious adverse events that occurred through week 24 were anaemia (10 [5%]), cardiac failure (5 [2%]), pyrexia (4 [2%]), and pneumonia (4 [2%]) with pacritinib, and anaemia (5 [5%]), sepsis (2 [2%]), and dyspnoea (2 [2%]) with BAT. Deaths due to adverse events were observed in 27 (12%) patients in the pacritinib group and 14 (13%) patients in the BAT group throughout the duration of the study. INTERPRETATION: Pacritinib therapy was well tolerated and induced significant and sustained SVR and symptom reduction, even in patients with severe baseline cytopenias. Pacritinib could be a treatment option for patients with myelofibrosis, including those with baseline cytopenias for whom options are particularly limited. FUNDING: CTI BioPharma Corp.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017. PMID: 28336242. doi:10.1016/S2352-3026(17)30027-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。